NVC-001 is designed to target the mechanobiological root cause of LMNA dilated cardiomyopathy and has disease-modifying potential SINGAPORE, PARIS and PHILADELPHIA, Oct. 8, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed to address the root causes of life-threatening cardiomyopathies, today announced that the first...
SHENZHEN, China, Aug. 16, 2025 /PRNewswire/ -- Energize Lab's Eiliko AI Charm Bot continues to ride the wave of AI enthusiasm, maintaining its hot streak since...
Net Profit Increased by 56.9% Year-on-year to US$5.0 million Strategic Pursuit of Growth: Venturing into the Home Healthcare Sector Financial Highlights ...